85例遗传性视网膜疾病儿童的组套临床基因检测
单中心回顾性病例系列纳入2014年1月至2016年7月转诊的85例无亲缘关系遗传性视网膜疾病(IRD)儿童,行105或177个IRD相关基因组套检测;78.8%(n=67)获 probable 分子诊断,CACNA1F和ABCA4突变最常见,作者建议将基因检测早期引入诊断路径。
要点
- 85例IRD儿童中78.8%(n=67)获 probable 分子诊断,常染色体显性7.5%(n=5)、X连锁25.4%(n=17)、常染色体隐性67.2%(n=45)。
- 另5.9%(n=5)仅检出单个ABCA4杂合变异,临床特征谱符合ABCA4视网膜病变。
- 84.7%(n=72)完成电生理诊断检查,其中81.9%(n=59)获 probable 分子诊断;CACNA1F和ABCA4突变分别占诊断的14.9%(n=10)和11.9%(n=8)。
核心结论
- 组套基因检测在84.7%的IRD儿童中指向分子诊断,该研究人群的诊断率显著高于既往报告的非选择IRD队列。
- 作者提出在具有提示IRD的临床和/或电生理发现的儿童中,于诊断路径早期引入基因检测。
研究设计与样本
- 单中心回顾性病例系列,纳入2014年1月至2016年7月转诊的85例无亲缘关系、诊断为孤立性或综合征性IRD的儿童。
- 行详细眼科检查,酌情行电生理诊断检查(EDT)和畸形学评估,以人类表型本体术语记录眼部和眼外特征。
- 在认证诊断实验室行多基因组套检测(105或177个IRD相关基因),随后进行临床变异解读。
主要发现
- 78.8%(n=67)获 probable 分子诊断,其中常染色体显性7.5%(n=5)、X连锁25.4%(n=17)、常染色体隐性67.2%(n=45)。
- 另5.9%(n=5)仅检出单个ABCA4杂合变异,全部具有符合ABCA4视网膜病变的临床特征谱。
- 84.7%(n=72)完成EDT,其中81.9%(n=59)获 probable 分子诊断;CACNA1F和ABCA4突变分别占诊断的14.9%(n=10)和11.9%(n=8)。
- 许多病例中基因检测有助于区分静止性与进展性IRD亚型,并及时建立精确诊断。
关键数值与推荐
- 主要结局指标为基因检测的诊断率和临床有用性。
- 组套检测覆盖105或177个IRD相关基因。
临床怎么用
- 作者提出在具有提示IRD的临床和/或电生理发现的儿童中,于诊断路径早期引入基因检测。
- 作者预期与本文所述类似的方法将成为小儿眼科诊疗的标准组成部分。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the clinical usefulness of genetic testing in a pediatric population with inherited retinal disease (IRD). DESIGN: Single-center retrospective case series. PARTICIPANTS: Eighty-five unrelated children with a diagnosis of isolated or syndromic IRD who were referred for clinical genetic testing between January 2014 and July 2016. METHODS: Participants underwent a detailed ophthalmic examination, accompanied by electrodiagnostic testing (EDT) and dysmorphologic assessment where appropriate. Ocular and extraocular features were recorded using Human Phenotype Ontology terms. Subsequently, multigene panel testing (105 or 177 IRD-associated genes) was performed in an accredited diagnostic laboratory, followed by clinical variant interpretation. MAIN OUTCOME MEASURES: Diagnostic yield and clinical usefulness of genetic testing. RESULTS: Overall, 78.8% of patients (n = 67) received a probable molecular diagnosis; 7.5% (n = 5) of these had autosomal dominant disease, 25.4% (n = 17) had X-linked disease, and 67.2% (n = 45) had autosomal recessive disease. In a further 5.9% of patients (n = 5), a single heterozygous ABCA4 variant was identified; all these participants had a spectrum of clinical features consistent with ABCA4 retinopathy. Most participants (84.7%; n = 72) had undergone EDT and 81.9% (n = 59) of these patients received a probable molecular diagnosis. The genes most frequently mutated in the present cohort were CACNA1F and ABCA4, accounting for 14.9% (n = 10) and 11.9% (n = 8) of diagnoses respectively. Notably, in many cases, genetic testing helped to distinguish stationary from progressive IRD subtypes and to establish a precise diagnosis in a timely fashion. CONCLUSIONS: Multigene panel testing pointed to a molecular diagnosis in 84.7% of children with IRD. The diagnostic yield in the study population was significantly higher compared with that in previously reported unselected IRD cohorts. Approaches similar to the one described herein are expected to become a standard component of care in pediatric ophthalmology. We propose the introduction of genetic testing early in the diagnostic pathway in children with clinical and/or electrophysiologic findings, suggestive of IRD.
引用
- Taylor RL, Parry NRA, Barton SJ, et al. Panel-Based Clinical Genetic Testing in 85 Children with Inherited Retinal Disease. Ophthalmology. 2017. PMID: 28341476. doi:10.1016/j.ophtha.2017.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。